James Thomas Coates, Ph.D. and his team at Decisive Point specialize in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking.
Cell line development involves multiple processes. Large numbers of clones are screened and selected on the basis of productivity and stability. An established platform for the rapid titer of antibody clones can enable quick selection of high-producing clones.
While numerous companies succeed in developing promising ADCs, manufacturing such complex and highly potent treatments presents unique challenges. Get an insider look at how these treatments make it from development to commercialization.